CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
about
Chimeric antigen receptor T-cell therapy for solid tumorsDifferent Subsets of T Cells, Memory, Effector Functions, and CAR-T ImmunotherapyMesothelin-Targeted CARs: Driving T Cells to Solid TumorsFCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.Clinical application of genetically modified T cells in cancer therapy.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsPredictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) AutoregulationAntibody-modified T cells: CARs take the front seat for hematologic malignancies.CAR T cells: driving the road from the laboratory to the clinic.CD28z CARs and armored CARsAdoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.CAR T-cell immunotherapy: The path from the by-road to the freeway?Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome.OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice.Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Synthetic immunology: T-cell engineering and adoptive immunotherapy
P2860
Q26750908-B563741C-94C4-45F6-9FF0-4C0398625916Q26752955-C7325B15-3772-4B45-928B-B1CE1C14D271Q26778759-6FD4E122-99B9-459B-8BF9-B6F45F0FF560Q33607015-5684788B-CA9E-49EE-8A05-497CFE826CE3Q34047847-55C0A069-E671-4D03-9DA4-E38C193098BCQ34511646-E4A567EF-3093-4E6E-8369-5FA82B29C073Q36470354-16A0BC80-1C8B-48D6-86D3-648BABA4049CQ37162653-C8DA6EF8-E846-4CCB-A320-9453EB11DFAEQ37723469-EC431E9B-1145-4901-9970-6BA0AEA06697Q38170499-F258DB4B-3109-414E-A1CB-5AD6A17050E7Q38199347-FAB3722D-AE99-4659-8524-ACF0D159C423Q38258842-F03DD68E-820B-42C2-8D22-35D8A5D9CD92Q38400420-34CF65A4-C018-422B-9326-B9DA50E24BDDQ38525034-2423006C-A9B2-4501-AA82-C8EE930B2989Q38632105-20EDF658-1859-44F0-867B-A7975A051407Q38666256-131DE80A-3C34-49AF-A31B-3FA488E72425Q38787449-91D02F7A-A019-4647-9783-7A05FA7D27C6Q39111432-9BDF58ED-77CB-4A36-8FC0-3F54CDED6B8CQ39360350-B8C63365-EC59-4350-A75C-AD65B45E644FQ39718346-E5FAEC2C-555B-49AC-AA97-CBF1F904F95BQ39832619-1E6FA98B-45DE-4766-A2E8-D362C8E487A7Q40782944-FBB75FBF-A90A-41B0-A028-DAD183C484FCQ41298215-4D5DE34E-2662-4C41-A28F-8C7C577617E0Q42060017-167E09B8-A393-4088-866C-D87C59961AEDQ42362413-BE87CC85-C464-4886-94F8-81060BE0C764Q45848557-EC6DA8B1-F8F5-47B4-8C1F-C054A2C1B57CQ49280922-3AF6D9F4-5E2E-4455-8BE5-E136688018BFQ57823195-441F5E3D-5C54-4690-B163-DC429898E8CE
P2860
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
CD28 costimulation Impairs the ...... by preventing Lck activation.
@en
CD28 costimulation Impairs the ...... by preventing Lck activation.
@nl
type
label
CD28 costimulation Impairs the ...... by preventing Lck activation.
@en
CD28 costimulation Impairs the ...... by preventing Lck activation.
@nl
prefLabel
CD28 costimulation Impairs the ...... by preventing Lck activation.
@en
CD28 costimulation Impairs the ...... by preventing Lck activation.
@nl
P2093
P2860
P356
P1433
P1476
CD28 costimulation Impairs the ...... by preventing Lck activation.
@en
P2093
Andreas A Hombach
Anja Hombach
Annette Schmidt
David M Kofler
Gunter Rappl
Hinrich Abken
Markus Chmielewski
Tobias Riet
P2860
P304
P356
10.1038/MT.2011.9
P577
2011-02-15T00:00:00Z